Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib expanded access for patients unable to swallow capsules
2024-000442-10Phase 4
- Sponsor
- Pfizer
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of crizotinib in Non-hematologic malignancy and hematopoietic malignancies, sponsored by Pfizer. Primary endpoints: Safety - serious adverse events and Safety - Grade 3-5 adverse events.
02
Drugs
crizotinib
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on 2024-000442-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000442-10.